Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventions
Copyright © 2021 Elsevier Inc. All rights reserved..
Infections of the Coronavirus SARS-CoV-2 continue to spread around the globe, causing Coronavirus Disease (COVID)-19. Infected people are at risk of developing acute interstitial pneumonia, which can result in lethal complications, particularly in patients with pre-existing co-morbidities. Novel prophylactic and therapeutic interventions are urgently needed to limit the infection-associated health risk for the population and to contain the pandemic. Animal models are indispensable to assessing the efficacy and safety of potential new antivirals, vaccines, and other innovative therapies, such as nucleic acid agonists of innate immune sensing receptors. In this review, we provide an overview of the commonly used animal models to study SARS-CoV-2 and COVID-19, including a summary of their susceptibility to infection, the spectrum of symptoms elicited, and the potential for drug development in each model. We hope that this review will help researchers to decide on the right model organism to quickly address their specific scientific questions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:228 |
|---|---|
| Enthalten in: |
Pharmacology & therapeutics - 228(2021) vom: 24. Dez., Seite 107931 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Renn, Marcel [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Animal models |
|---|
| Anmerkungen: |
Date Completed 23.12.2021 Date Revised 07.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.pharmthera.2021.107931 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327184361 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327184361 | ||
| 003 | DE-627 | ||
| 005 | 20231225200219.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.pharmthera.2021.107931 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1090.xml |
| 035 | |a (DE-627)NLM327184361 | ||
| 035 | |a (NLM)34171328 | ||
| 035 | |a (PII)S0163-7258(21)00133-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Renn, Marcel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventions |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.12.2021 | ||
| 500 | |a Date Revised 07.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier Inc. All rights reserved. | ||
| 520 | |a Infections of the Coronavirus SARS-CoV-2 continue to spread around the globe, causing Coronavirus Disease (COVID)-19. Infected people are at risk of developing acute interstitial pneumonia, which can result in lethal complications, particularly in patients with pre-existing co-morbidities. Novel prophylactic and therapeutic interventions are urgently needed to limit the infection-associated health risk for the population and to contain the pandemic. Animal models are indispensable to assessing the efficacy and safety of potential new antivirals, vaccines, and other innovative therapies, such as nucleic acid agonists of innate immune sensing receptors. In this review, we provide an overview of the commonly used animal models to study SARS-CoV-2 and COVID-19, including a summary of their susceptibility to infection, the spectrum of symptoms elicited, and the potential for drug development in each model. We hope that this review will help researchers to decide on the right model organism to quickly address their specific scientific questions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Animal models | |
| 650 | 4 | |a Antiviral immunity | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Vaccine | |
| 650 | 4 | |a Virus | |
| 700 | 1 | |a Bartok, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Zillinger, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Hartmann, Gunther |e verfasserin |4 aut | |
| 700 | 1 | |a Behrendt, Rayk |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacology & therapeutics |d 1981 |g 228(2021) vom: 24. Dez., Seite 107931 |w (DE-627)NLM000442402 |x 1879-016X |7 nnns |
| 773 | 1 | 8 | |g volume:228 |g year:2021 |g day:24 |g month:12 |g pages:107931 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.pharmthera.2021.107931 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 228 |j 2021 |b 24 |c 12 |h 107931 | ||